Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX210c in amyotrophic lateral sclerosis
NCT06365216Phase 2Active, not recruiting
- Sponsor
- Axoltis Pharma
- Start
- Oct 2024
- Primary completion
- Feb 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nx210c in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Axoltis Pharma. Primary endpoints: Blood Neurofilament Light Chain at 6 weeks and Blood-Brain Barrier Integrity Biomarker at 6 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
nx210c
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06365216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365216.